Luvometinib is a mitogen-activated protein kinase ( MEK ) inhibitor with antitumor activity [1].
References:
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 38, No. 2, 2024.
References:
[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 38, No. 2, 2024.
















